Literature DB >> 24839009

CD243 gene polymorphism significantly associated with breast cancer susceptibility.

Weirong Yao1, Rongzeng Yan, Lin Ma, Huiping Wan, Yanmin Yu, Xia Cheng, Yingliang Li.   

Abstract

We aimed to obtain a summary risk estimate for CD243 gene polymorphism associated with breast cancer. A total of nine case-control studies, including 5,073 cancer patients and 7,498 control subjects, were pooled in our fixed effects meta-analysis of the association between CD243 gene polymorphism and risk of breast cancer. All data were analyzed by using Stata software (version 12.0). We found significant risk effects under TT vs. TC + CC genetic model [odds ratio (OR) = 1.09, 95 % confidence interval (CI) = 1.01-1.18, P = 0.516], but not in other comparisons. Stratifying the pooled data by ethnicity and source of controls revealed that the association between the T allele and an increased risk of breast cancer was more pronounced among Asians (TT vs. CC: OR = 1.26, 95 % CI = 1.02-1.57, P = 0.720; TT vs. TC + CC: OR = 1.31, 95 % CI = 1.07-1.61, P = 0.708) and hospital-based studies (TT vs. CC: OR = 1.25, 95 % CI = 1.02-1.53, P = 0.877; TT vs. TC + CC: OR = 1.27, 95 % CI = 1.05-1.53, P = 0.540). No notable heterogeneity was indicated across studies. Our meta-analysis demonstrates that CD243 gene polymorphism may act as a predisposition factor for breast cancer, particularly in Asian populations.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24839009     DOI: 10.1007/s13277-014-2078-7

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  35 in total

Review 1.  Pharmacogenetics in the treatment of breast cancer.

Authors:  V Stearns; N E Davidson; D A Flockhart
Journal:  Pharmacogenomics J       Date:  2004       Impact factor: 3.550

2.  Roles of ABCB1 gene polymorphisms and haplotype in susceptibility to breast carcinoma risk and clinical outcomes.

Authors:  Huizhe Wu; Hui Kang; Yong Liu; Weiwei Tong; Duo Liu; Xiuli Yang; Minqiong Lian; Weifan Yao; Haishan Zhao; Desheng Huang; Xianzheng Sha; Enhua Wang; Minjie Wei
Journal:  J Cancer Res Clin Oncol       Date:  2012-04-19       Impact factor: 4.553

3.  Association between two polymorphisms of ABCB1 and breast cancer risk in the current studies: a meta-analysis.

Authors:  Pei-Hua Lu; Mu-Xin Wei; Jie Yang; Xiao Liu; Guo-Qing Tao; Wei Shen; Min-Bin Chen
Journal:  Breast Cancer Res Treat       Date:  2010-07-13       Impact factor: 4.872

4.  ABCB1 and GST polymorphisms associated with TP53 status in breast cancer.

Authors:  Silje H Nordgard; Marylyn D Ritchie; Sigrid D Jensrud; Alison A Motsinger; Grethe I G Alnaes; Gordon Lemmon; Marianne Berg; Stephanie Geisler; Jason H Moore; Per Eystein Lønning; Anne-Lise Børresen-Dale; Vessela N Kristensen
Journal:  Pharmacogenet Genomics       Date:  2007-02       Impact factor: 2.089

5.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

6.  Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance.

Authors:  B J Trock; F Leonessa; R Clarke
Journal:  J Natl Cancer Inst       Date:  1997-07-02       Impact factor: 13.506

7.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

8.  Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene.

Authors:  Deanna L Kroetz; Christiane Pauli-Magnus; Laura M Hodges; Conrad C Huang; Michiko Kawamoto; Susan J Johns; Doug Stryke; Thomas E Ferrin; Joseph DeYoung; Travis Taylor; Elaine J Carlson; Ira Herskowitz; Kathleen M Giacomini; Andrew G Clark
Journal:  Pharmacogenetics       Date:  2003-08

9.  Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease.

Authors: 
Journal:  Lancet       Date:  2002-07-20       Impact factor: 79.321

10.  The association between polymorphisms in the MDR1 gene and risk of cancer: a systematic review and pooled analysis of 52 case-control studies.

Authors:  Ling-Hui Wang; Yan-Bin Song; Wen-Ling Zheng; Ling Jiang; Wen-Li Ma
Journal:  Cancer Cell Int       Date:  2013-05-20       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.